Amgen And Kite Partner For Cancer Therapy
Uri Gruenbaum | Jan 07, 2015 08:32AM ET
On January 5th, biopharmaceutical company Amgen Inc. (NASDAQ:AMGN) announced plans to collaborate with Kite Pharma (NASDAQ:KITE) on cancer treatments. The two pharmaceutical companies will join forces to research, develop, and commercialize a cancer therapy using existing drugs and research from both companies.
Sean E. Harper, M.D., executive vice president at Amgen, stated, “The intersection of immunology and oncology represents one of the most promising approaches to delivering significant impact for patients with cancer. With our existing immuno-oncology portfolio of cutting-edge technologies and expertise, we believe joining forces with Kite Pharma will leverage our targets and their leading CAR T cell platform to advance another new promising therapeutic approach to fight cancer."
In other news, Amgen shares hit an all-time high of $173.14 in October. A few weeks later on December 17th, Amgen announced a 30% dividend increase declared at $0.79, available to all stock holders as of February 12th.
A handful of analysts rated Amgen in light of the announcement to partner with Kite Pharma, along with forward looking statements toward 2015.
On January 6th, analyst Anthony Butler of Barclays (LONDON:BARC) initiated coverage of Amgen with an Equal-weight rating and a $180 price target. Butler noted that Amgen will have a hard time sustaining momentum going forward in 2015.
Anthony Butler has an 83% overall success rate recommending stocks from the past year with a +32.4% average return per recommendation.
Separately on January 5th, analyst Cory Kasimov of J.P. Morgan reiterated a Neutral rating on Amgen with a price target of $163. Kasimov noted, “Given [Amgen’s] capital allocation strategy, we believe AMGN offers investors a differentiated investment opportunity vs. other biotechs, which likely contributed to its outperformance in 2014.” He continued, “At this point, however, we believe the near-term potential of new drugs… is largely appreciated by investors… We do believe that recent cost cutting will help the bottom line, and the [company’s] position as the only dividend-issuing biotech should continue to attract generalist interest.” Kasimov concluded, “Bottom line, we believe AMGN’s pipeline and future business mix… are attractive, but with shares meaningfully higher in 2014… we have a hard time finding additional near-term levers for relative upside. Thus, we are maintaining a Neutral rating, but increasing our YE15 PT to $163 from $130.”
Get The News You Want
Cory Kasimov has a 50% success rate rating stocks over the past year with a +16.6% average return per recommendation.
On average, the top analyst consensus for AMGN on TipRanks is Hold.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.